Advertisement

Topics

Acura to provide Aversion Technology to KemPharm

19:00 EDT 18 Oct 2016 | Pharmaceutical Technology

US-based Acura Pharmaceuticals has signed a license agreement to provide its Aversion Technology to KemPharm to use with its existing and in-development immediate release (IR) opioid product candidates.

Original Article: Acura to provide Aversion Technology to KemPharm

NEXT ARTICLE

More From BioPortfolio on "Acura to provide Aversion Technology to KemPharm"

Quick Search
Advertisement
 

Relevant Topic

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...